Commercial has made over 1 trades of the AIM ImmunoTech Inc stock since 2006, according to the Form 4 filled with the SEC. Most recently Commercial sold 1,096,572 units of AIM stock worth $7,072,889 on 17 March 2006.
The largest trade Commercial's ever made was selling 1,096,572 units of AIM ImmunoTech Inc stock on 17 March 2006 worth over $7,072,889. On average, Commercial trades about 1,096,572 units every 0 days since 2006.
You can see the complete history of Commercial First stock trades at the bottom of the page.
Commercial's mailing address filed with the SEC is 800 SHADES CREEK PARKWAY, , BIRMINGHAM, AL, 35209.
Over the last 20 years, insiders at AIM ImmunoTech Inc have traded over $15,026,013 worth of AIM ImmunoTech Inc stock and bought 898,126 units worth $656,210 . The most active insiders traders include Thomas K Equels, J Mervyn Nabors oraz Commercial Bank First. On average, AIM ImmunoTech Inc executives and independent directors trade stock every 125 days with the average trade being worth of $16,943. The most recent stock trade was executed by Thomas K Equels on 6 May 2024, trading 61,729 units of AIM stock currently worth $25,309.
aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as
AIM ImmunoTech Inc executives and other stock owners filed with the SEC include: